Published in Ophthalmology
http://www.ncbi.nlm.nih.gov/pubmed/26411836

Title

Diagnostic accuracy of technologies for glaucoma case-finding in a community setting

Authors

Priya L Dabasia (PhD, MCOptom)[1]
Bruno R Fidalgo (MSc, MOptom)[1]
David F Edgar (FCOptom)[1]
David F Garway-Heath (MD, FRCOphth)[2]
John G Lawrenson (PhD, FCOptom)[1]

Institutions

[1] Centre for Public Health Research, School of Health Sciences, City University London, UK
[2] National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK

Corresponding author

John G Lawrenson (PhD, FCOptom)

Meeting Presentation

- European Association for Vision and Eye Research, October 2014
- British Congress of Optometry and Vision Science, September 2014

Financial support

The iVue Optical Coherence Tomographer used in this study was loaned by Optovue Inc., which also provided a part-proportion of funding for the technician to undertake the index tests during data collection. Optovue Inc. made suggestions at the protocol stage of the study but had no input in the data analysis and interpretation. The College of Optometrists, UK provided a PhD studentship to Priya Dabasia to conduct this work, and had no role in the design or conduct of this research. DFG-H is funded in part by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Moorfields Eye Hospital and UCL Institute of Ophthalmology. The views expressed are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research, or the Department of Health. DFG-H's chair at UCL is supported by funding from the International Glaucoma Association.

Conflict of interest

Dr. Garway-Heath reports personal fees from Heidelberg Engineering, grants from National Institute for Health Research (HTA), outside the submitted work. In addition, Dr. Garway-Heath has a patent ANSWERS pending.

Running head

Accuracy of technologies for glaucoma case-finding

Address for reprints

City University London
Division of Optometry and Visual Science
First floor, Myddleton Street Building
1 Myddleton Street
London
EC1R 1UW

This article contains additional online-only material. The following should appear online-only: Table 1, Table 2, Table 4, Table 6, and Figure 3.

Abstract

Purpose: To assess the case-finding performance of the Frequency Doubling Technology perimeter (FDT), Moorfields Motion Displacement Test (MMDT), iVue Optical Coherence Tomographer (OCT) and Ocular Response Analyser (ORA), used alone or combined, for suspect and definite primary open angle glaucoma (POAG).

Design: Cross-sectional, observational, community-based study.

Participants: 505 subjects aged 60 years and older recruited from a community setting using no pre-defined exclusion criteria.

Methods: Subjects underwent 4 index tests conducted by a technician unaware of subjects' ocular status. FDT and MMDT were used in suprathreshold mode. iVue OCT measured ganglion cell complex and retinal nerve fibre layer (RNFL) thickness. The reference standard was a full ophthalmic examination by an experienced clinician, masked to index test results. Subjects were classified as POAG (open drainage angle, glaucomatous optic neuropathy, and glaucomatous field defect), glaucoma suspect, ocular hypertension (OHT) or non-POAG/non-OHT.

Main Outcome Measures: Test performance evaluated the individual as unit of analysis. Diagnostic accuracy was initially assessed using predefined cut-offs for abnormality to generating sensitivity, specificity, and likelihood ratios.

Continuous data were used to derive estimates of sensitivity at 90% specificity, and partial area under the curve of receiver operating characteristic (AUROC) plots from 90% to 100% specificity.

Results: From the reference standard examination, 26 (5.1%) subjects were POAG and 32 (6.4%) glaucoma suspects. Sensitivity (95% confidence interval) at 90% specificity for detection of glaucoma suspect/POAG combined was 41% (28 to 55) for FDT, 35% (21 to 48) for MMDT, and 57% (44 to 70) for best-performing OCT parameter (inferior quadrant RNFL thickness); for POAG, sensitivity was 62% (39 to 84) for FDT, 58% (37 to 78) for MMDT, and 83% (68 to 98) for inferior quadrant RNFL thickness. The partial AUROC was significantly greater for inferior RNFL thickness than visual-function tests ($p<0.001$). Post-test probability of glaucoma suspect /POAG combined and definite POAG increased substantially when best-performing criteria were combined for FDT or MMDT, iVue OCT and ORA.

Conclusions: Diagnostic performance of individual tests gave acceptable accuracy for POAG detection. The low specificity of visual-function tests precludes their use in isolation, but case-detection improves by combining RNFL thickness analysis with visual-function tests.

Open angle glaucoma (OAG) is a major cause of visual morbidity, accounting for 10.6% to 13.5% of blindness in high-income countries.[1] However, epidemiological studies in developed countries consistently demonstrated that approximately half of those with OAG remained undetected using current case-finding strategies. [2-8]

OAG satisfies Wilson-Jungner criteria for the condition and treatment ideally required to initiate a screening programme.[9] In 2012, a Comparative Effectiveness Review by the Agency for Healthcare Research and Quality concluded that limited evidence existed on the effectiveness of screening for OAG in adult populations.[10] An earlier UK-based economic modelling study reported that population screening at any age was not cost-effective, but stronger evidence existed in support of targeted screening of high-risk groups.[11] A strategy for improving screening cost-effectiveness was proposed, involving initial technology-based assessment, allowing an enriched population to be referred for office-based assessment by an ophthalmologist or optometrist. In the context of case-finding for a low prevalence disease in the general population, an ideal screening test must be simple, fast and combine high specificity (above 90%), with acceptably high sensitivity. However, a 2008 systematic review found no single test, used alone or in combination, provided sufficiently high accuracy for OAG detection.[12] The review highlighted a dearth of high-quality diagnostic accuracy studies for OAG detection. In many cases, reliability and applicability of study findings are limited by methodology, with failure to satisfy the quality assessment of diagnostic accuracy studies (QUADAS) criteria.[13]

This study aims to determine diagnostic accuracy of modern imaging and visual function testing technologies, used alone and in combination, for detecting OAG in a representative sample of the primary-care population, compared to a reference standard ophthalmic examination including standard automated perimetry (SAP). The study was designed, and findings reported in accordance with Standards for Reporting of Diagnostic Accuracy (STARD) criteria.[14]

Methods

This prospective cross-sectional study was conducted in one university-based community eye clinic in London, UK, during 12 months from September 2012. The study was approved by the institutional review board and adhered to the Declaration of Helsinki tenets. All subjects provided written informed consent. Males and females aged 60 years and older were recruited. Study information, together with an invitation to participate, was distributed locally through neighbouring optometry practices and community groups. To ensure a representative sample of the eligible population, no pre-defined exclusion criteria were specified; subjects with known POAG or other ocular morbidities were included.

All subjects underwent a series of technology-based index tests, followed by a reference standard ophthalmic examination on the same day. Figure 1 shows the study flow diagram. Thresholds of abnormality for the index tests were based on cut-offs commonly reported in previous literature, manufacturers' suggested cut-offs, and comparisons with internal normative databases, and were specified in the protocol prior to data analysis. The technology-based assessment comprised four index tests and was performed by a single, experienced technician with no prior knowledge of subjects' ocular status or findings from the reference standard ophthalmic examination. All equipment used for tests performed during the reference standard ophthalmic examination and technology-based assessment was calibrated daily in accordance with manufacturers' instructions, and examinations were

undertaken in dedicated research rooms based in the community eye clinic to ensure a consistent and reliable testing environment over the 12-month period.

Visual function tests (FDT and MMDT)

The first generation frequency doubling technology (FDT; Carl Zeiss Meditec, Inc., Dublin, CA) perimeter was used in C20-5 suprathreshold mode (software version 4.00.0). Contrast thresholds are evaluated at 17 locations within the central 20º of visual field. A detailed description of measurement principles has been described elsewhere.[15] An abnormal result was defined using two cut-offs: a) one or more location(s) missed at the p<5% significance level and b) one or more location(s) missed at the p<1% significance level. Further analysis was performed using a scoring system described by Patel et al. which allocates an overall score between 0 and 87 for each FDT result, giving increased importance to more severe defects and locations missed closer to fixation.[16]

The Moorfields motion displacement test (MMDT; Moorfields Eye Hospital, London, UK) is a prototype perimeter based on a form of temporal hyperacuity, in which subjects identify oscillation of a vertical bar, the threshold being the smallest displacement seen. Testing was performed using the Enhanced Standard Threshold Algorithm (ESTA) 99.5 suprathreshold program (Pandora, software version v1.7.10) (see http://www.moorfieldsmdt.co.uk/clinicians.asp for more details on MMDT technology). The test presents 31 stimuli on a standard laptop LCD display. Displacements seen or not seen are recorded on a pass-fail plot, and this information is used together with the ESTA spatial

filter to generate a probability plot that provides an estimate of the 'probability of true damage' (PTD) between 0 and 100 at each test location. In the present study, an abnormal plot was defined by the developers' recommended threshold of a global PTD ≥3.0.

The testing order between FDT and MMDT was randomized, and these examinations were never performed in immediate succession. Tests were repeated once if one or more locations were missed, or if the result was unreliable (Table 1, available at www.aaojournal.org).

iVue Spectral Domain OCT (SD-OCT)

The iVue optical coherence tomographer (OCT; Optovue Inc., Fremont, CA) is a compact version of the RTVue OCT. Diagnostic data for OAG detection were obtained using the ganglion cell complex (GCC) protocol of the iWellness scan, and glaucoma optic nerve head (ONH) retinal nerve fibre layer (RNFL) scan patterns in software version V3.2.0.42 (details of scan protocols are described elsewhere[17]). Scans were initially captured through undilated pupils in dark-room illumination, and repeated following pupil dilation if data quality failed to meet manufacturers' guidelines (8%, 81 of 1009 eyes).

Of the structural parameters for GCC and RNFL thickness, the overall mean, superior hemifield and inferior hemifield thickness were analysed. RNFL thickness was further evaluated by hourglass quadrant: temporal 316 to 45 degrees, superior 46 to 135 degrees, nasal 136 to 225 degrees, and inferior 226 to 315 degrees. GCC thickness data were also represented by two

additional parameters which analyse the pattern of GCC loss using differing levels of focality: Global loss volume (GLV) and Focal loss volume (FLV). Descriptions of procedures deriving these parameters have been reported previously.[18-20] The defined cut-off for abnormality was any RNFL or GCC parameter falling outside the 99% normal limit based on manufacturers' integrated normal database.

Ocular response analyzer (ORA)

The ORA (Reichert Ophthalmic Instruments, Depew, NY, USA) is an air-puff tonometer which uses a bi-directional applanation sequence to derive two measures of corneal biomechanical properties: corneal hysteresis (CH) and corneal resistance factor (CRF), and two intraocular pressure (IOP) parameters: IOPg (Goldmann-correlated) and IOPcc (Cornea-compensated).[21] A minimum of four measurements from each eye was acquired (software version 3.01). The highest waveform score (WS) measurement was used for analysis provided multiple measurements with similar graphical outputs had been attained[22] with a WS of 3.5 or greater.[22, 23] IOPg or IOPcc above 21mmHg was defined as the cut-off for abnormality.

Reference standard ophthalmic examination

All subjects underwent a series of standard tests for glaucoma by an experienced clinician, trained and validated in glaucoma according to UK practice, and masked to results of the preceding index tests. Validation of the reference standard examiner was confirmed by competency-based assessment, with results being compared with classification by a consultant

glaucoma sub-specialist ophthalmologist. Kappa agreement for combined and separate assessment of the optic disc and visual field ranged from 0.70 to 0.89.

Visual field testing was performed with the Humphrey Field Analyzer (HFA; Carl Zeiss Meditec, Inc., Dublin, CA) and the Swedish Interactive Thresholding Algorithm (SITA) 24-2 standard pattern (Model 720i, software version 5.1.2). Where possible, HFA was repeated for unreliable results (false negative responses or fixation losses >33%, false positive responses >15%) and Glaucoma hemifield test (GHT) recordings of 'outside normal limits'. Following full anterior segment assessment by biomicroscope, and measurement of IOP by Goldmann Applanation Tonometer, eyes with a potentially occludable angle identified by the van Herick test[24] were evaluated by gonioscopy. Detailed posterior segment examination was performed through dilated pupils using indirect ophthalmoscopy and fundus photography (Topcon TRC-NW8F). Subjects were asked to complete a questionnaire regarding the acceptability of each index test.

The following criteria were used for classification of subjects as definite POAG or as glaucoma suspect based on observations from one or both eyes:

- Definite POAG: open anterior chamber angle, presence of glaucomatous optic neuropathy (either localised absence of neuro-retinal rim, cup/disc ratio (CDR) of ≥0.7 or inter-ocular asymmetry in vertical CDR of ≥0.2 in similar sized discs) and the presence of a concordant glaucomatous field defect based on criteria amended from Anderson and Patella[25] (a cluster of

≥3 points on the pattern deviation plot having p<5% with at least one point with p<1%, none of which can be edge points unless located immediately above or below the nasal horizontal meridian, AND pattern standard deviation (PSD) p<5%, AND GHT 'outside normal limits').

- Glaucoma suspect: included 'disc suspects' showing features of glaucomatous optic neuropathy but with normal or equivocal fields, and subjects with visual field defects but without concordant disc damage (see 'Definite POAG' above for definitions of glaucomatous optic neuropathy and visual field defects).

The ocular hypertension (OHT) case definition in this study for subjects not taking IOP-lowering medication was based on measurement of IOP above 21mmHg on two separate occasions, with open anterior chamber angles and neither visual field plots nor optic discs meeting the criteria for abnormality.

Sample size calculation

The sample size was based on an anticipated sensitivity of the index tests to detect POAG (based on current case definitions) of 0.75[12] with a minimal acceptable precision of the sensitivity estimate of ±0.25 with 0.95 probability. This requires 42 POAG cases. Since prevalence of suspected and definite POAG in the local elderly population would be approximately 10%[26] it was estimated that at least 420 subjects needed to be recruited.

Statistical analysis

Statistical analysis was performed using SPSS 21.0 software (www.ibm.com/SPSS_Statistics), Medcalc 14.8.1 (www.medcalc.org), and STATA 13.0 (StataCorp. 2013. College Station, TX: StataCorp LP, www.stata.com). Index data were analysed masked to findings from the reference ophthalmic examination. Unreliable results acquired by visual function tests (FDT and MMDT), and data from repeatedly poor quality ORA and OCT acquisitions were removed from analysis. The unit of analysis was the individual, and the comparison was between the most abnormal index test result from either the right or left eye and the overall reference standard classification.

Differences in mean values for demographic characteristics between diagnostic groups were evaluated by ANOVA for normally distributed data, and Kruskal-Wallis test for data with skewed distributions, each together with post-hoc analysis. For all tests, $p<0.05$ was considered statistically significant. Initial diagnostic accuracy estimates of each index test to detect glaucoma suspect/definite POAG combined and definite POAG were evaluated using the predefined cut-offs for abnormality to generate sensitivity, specificity and likelihood ratios with 95% confidence intervals. To compare index test performance within a clinically relevant range for detection of a low prevalence disease we determined the sensitivity at 90% specificity, and normalized the partial AUROC curves to determine the average sensitivity[27] between 90% and 100% specificity. To test for any statistically significant differences between sensitivity at set specificity, and partial AUROC curve estimates the Wald test was used.[28] Best performing structural and functional criteria were combined in

311 series to calculate sensitivity and specificity values, and change from pre-test
312 to post-test probability estimates of a given subject having POAG were
313 determined using Bayesian reasoning.

Results

505 subjects entered the study (59% female and 41% male), aged between 60 and 92 years with median (interquartile range) age being 68 (59 to 77) years. Self-reported ethnicities were 88% White, 8% South Asian, 2% Black, 1% Chinese, and 1% 'other'. Based on the reference standard examination, 26 (5.1%) subjects were classified as definite POAG, 32 (6.4%) glaucoma suspect, and 17 (3.4%) OHT. Using Hodapp-Parrish-Anderson criteria,[29] 11 (42%) definite POAG cases were classified as early, 6 (23%) as moderate and 9 (35%) as advanced. Demographic and summary clinical data for each group are summarised in Table 2, available at www.aaojournal.org. A high proportion of subjects had ocular co-morbidities, including 9.5% with moderate or advanced AMD and 10.7% with clinically-significant cataract in one or both eyes. Following repeat examination, over 95% of results acquired using each of the four index tests were reliable or of sufficient quality for analysis (Table 1, available at www.aaojournal.org).

Diagnostic performance of visual-function tests

A FDT performance cut-off of 1 or more missed location at p<5% level of significance, representing the most common threshold for abnormality in published literature, yielded 72.4% (CI 59.8 to 82.3) sensitivity and 66.7 (CI 62.1 to 71.0) specificity for detection of glaucoma suspect/POAG combined (Table 3). Using the same cut-off, sensitivity to detect POAG alone was 92.3% (CI 75.9 to 97.9) and specificity 65.2% (60.8 to 69.3). Test specificity improved to 79.1% (CI 75.2 to 82.5) using a test failure cut-off of 1 or more location(s) missed at p<1% level of significance, while retaining a sensitivity of 88.5% (CI

71.0 to 96.0) for POAG detection (Table 3). The developers' recommended MMDT performance cut-off (global PTD ≥3.0) achieved test specificity of over 80% but lower sensitivity of 51.7% (CI 39.2 to 64.1) for glaucoma suspect/POAG combined, and 65.4% (CI 46.2 to 80.6) for POAG detection. Notably, all (100%) cases of moderate and advanced POAG (mean deviation worse than -6dB) were detected by both perimetry index tests. Of the 11 POAG subjects classified with early disease (-6dB or better), only 2 subjects (18%) were test positive using MMDT (global PTD ≥3.0), compared with 9 subjects (82%) detected by the less specific FDT criterion (1 or more missed location at p<5% level of significance).

Diagnostic performance of the SD-OCT

Best performing parameters based on highest test sensitivity for detection of glaucoma suspect /POAG combined were GCC FLV (46.6%, CI 34.3 to 59.2), and inferior quadrant RNFL thickness (46.6%, CI 34.3 to 59.2). A similar trend followed for detection of POAG (GCC FLV 73.1%, CI 53.9 to 86.3; inferior quadrant thickness 76.9%, CI 57.9 to 89.0) (Table 3). Notably, all 5 GCC and 7 RNFL parameters included for analysis individually provided a test specificity exceeding 90%. In particular, GCC GLV was 97.9% (CI 96.2 to 98.8) specific for discrimination of definite POAG, with the highest positive likelihood ratio of 21.8 (CI 10.4 to 45.8) of all iVue parameters (Table 4, available at www.aaojournal.org). However, a threshold of abnormality defined by any of the 7 RNFL parameters exceeding the 99% normative level provided further diagnostic value by improving sensitivity to 62.1% (CI 49.2 to 73.4) for glaucoma suspect/POAG combined and 88.5% (CI 71.0 to 96.0) for POAG

while achieving specificity above 88%. Using the same cut-off, sensitivity improved to 93.3% (CI 70.2 to 98.8) for distinguishing POAG subjects with moderate and advanced POAG. Moreover, 25 of the 26 (96.1%, CI 81.1 to 99.3) subjects classified as POAG in the reference ophthalmic examination were detected by one or more GCC or RNFL parameter exceeding the 99% normative interval (see Table 3) for a specificity of 81.3% (77.5 to 84.6).

IOP estimates of IOPcc and IOPg generated by the ORA had little diagnostic value for distinguishing glaucoma suspect and POAG subjects from the rest of the sample.

ROC analysis

Sensitivity at 90% specificity, and partial AUROC curve for 90% to 100% specificity are summarized in Table 5 (see Table 6, available at www.aaojournal.org for data on total AUROC curves). Overall, inferior quadrant RNFL thickness measured using the iVue SD-OCT was best performing parameter, providing highest sensitivity (56.9%, CI 44.2 to 69.6 glaucoma suspect/POAG combined; 82.8%, CI 67.6 to 97.9 POAG) and partial AUROC curve estimate (0.46, CI 0.34 to 0.58 glaucoma suspect/POAG combined; 0.70, CI 0.53 to 0.86 POAG) from 90% to 100% specificity. In fact, inferior quadrant RNFL thickness was statistically significantly superior to each of the visual function tests, based on partial AUROC curve estimates (glaucoma suspect/POAG combined FDT and MMDT $p<0.001$; POAG FDT and MMDT $p<0.001$) (Figure 2). Of the visual-function tests, FDT Patel et al. score (2000) achieved higher sensitivity (61.5%, CI 39.4 to 83.6) but a lower

partial AUROC curve result (0.35, CI 0.18 to 0.52) compared with MMDT global PTD (57.7%, CI 37.4 to 78.0 sensitivity, 0.44, CI 0.26 to 0.61 partial AUROC curve) for ranges starting from 90% specificity for distinguishing POAG from the rest of the sample, but these observations did not represent a statistically significant difference (sensitivity at set specificity p=0.598, partial AUROC curve p=0.248) (Figure 2).

Combining index test results

The combination of inferior quadrant RNFL thickness (p<1%) with FDT (1 or more location(s) missed at p<5% level) in which failure of either test is indicative of abnormality achieves a sensitivity of 79.3% (CI 67.2 to 87.7) for glaucoma suspect/POAG combined and 100.0% (CI 87.1 to 100.0) for POAG detection but with a marked reduction in specificity (glaucoma suspect/ POAG combined 63.3, CI 58.9 to 67.6; POAG 65.2, CI 60.7 to 69.5). On the other hand, stipulating that failure of both tests was indicative of POAG improved specificity to 96.8% (CI 94.8 to 98.1), but this did not represent a statistically significant improvement above test specificity of 95.0% (CI 92.6 to 96.6) achieved by inferior quadrant thickness alone (McNemar, p=1.0). Notably, the combination of iVue SD-OCT RNFL inferior quadrant parameter (p<1%) with FDT (1 or more missed location at p<5% level) detected all 26 subjects classified as POAG (Figure 3, available at www.aaojournal.org).

To further evaluate the diagnostic value of combining index test data using Bayesian probabilistic reasoning, best-performing parameters and cut-offs for abnormality were selected using the highest positive likelihood ratios (Table 4,

available at www.aaojournal.org). The probability estimate of a given subject having POAG rose from 5% (pre-test probability) to over 85% (post-test probability) when visual function tests (FDT, 1 or more missed location at p<1% level or MMDT, global PTD ≥3.0) were combined in series with best performing structural parameters (RNFL inferior quadrant thickness or GCC GLV, p<1%), and ORA IOPcc (>21mmHg). Using these test cut-offs, a post-test probability over 90% was achieved for detection of glaucoma suspect/POAG combined, rising from a pre-test probability of 11.5%.

Discussion

Currently, a national population-based screening programme for OAG has not been implemented in any country. An economic modeling study undertaken in Finland determined that an organized screening programme for glaucoma could be a cost-effective strategy compared to opportunistic case-finding, especially in older age groups.[30] A UK-based study using a similar approach to evaluate the clinical and cost-effectiveness of screening for POAG proposed the use of tonometry combined with an initial technology-based assessment, which would allow an enriched population to be referred for an office-based assessment by an ophthalmologist.[11] Alternatively, clinical data collected from a technology-based assessment could be transferred digitally and evaluated in a virtual clinic by a glaucoma specialist to improve the positive predictive value of referrals for further ophthalmic investigation.[31, 32] Cost-effectiveness may be improved by implementing a screening programme that targeted a number of sight-threatening eye diseases.

The current study evaluated the diagnostic performance of structural and visual function tests for the detection of glaucoma in a population of elderly subjects, representative of the target population for screening, in which pathologies other than glaucoma may be present. Data were analyzed using the individual as the unit of analysis. The performance of the FDT using the C20-5 screening program was similar to that reported in previous population screening studies.[33, 34] However, there has only been one published diagnostic accuracy study evaluating the MMDT.[35] This study found sensitivities and specificities of greater than 85%. It is likely that the lower performance of the

MMDT in the current study relates to the high levels of ocular co-morbidity typical of an elderly population, which may have impacted on the overall performance of the vision-function tests. ROC analysis of the FDT and MMDT, based on sensitivities at set specificities and partial AUROC, showed no statistical difference in performance between the two tests for the detection of POAG. However, in view of the MMDTs greater portability, ease of use and relatively lower cost it warrants further evaluation in population studies to further determine its potential as a screening test for glaucoma.

The iVue OCT is a recently developed compact SD-OCT and this is the first study to investigate its diagnostic performance for glaucoma detection using its in-built normative database. The structural parameters selected for the analysis and associated pass-fail criteria (value outside the 99% confidence interval) were established *a priori*. The best performing individual structural parameter (inferior quadrant RNFL thickness) provided a sensitivity of over 75% with a specificity of 95%, which may reflect the vulnerability of the inferior quadrant of the optic disc to glaucomatous damage.[36, 37] The OCT was particularly effective in identifying subjects with glaucoma, for example using a criterion of any structural parameter at the p<1% level the OCT would have identified 25 of 26 glaucoma subjects in our sample. ORA-derived IOP estimates were of limited diagnostic value in our population as half of the 26 glaucoma subjects were already receiving IOP-lowering therapy or had previously undergone surgical or laser interventions.

Early detection and treatment of glaucoma reduces the rate of progression of glaucomatous vision loss and visual field defects,[38, 39] which is likely to result in a better health-related quality of life for those affected, but concerns have been raised as to the potential overtreatment of individuals who may not be at significant risk of developing advanced glaucoma and visual impairment in their lifetime.[11] A retrospective UK study using a large visual field dataset, and modelling projected field loss in the patients' remaining lifetime, determined that only 5.2% of patients were at risk of progressing to statutory blindness in both eyes; more than 90% of these had a visual field mean deviation worse than -6dB in one or both eyes at presentation.[40] Given that the likelihood of patients suffering significant visual impairment is linked to the level of VF loss at presentation, it is notable that 100% of those in the current study with moderate or advanced glaucoma (mean deviation worse than -6dB) were detected by either the FDT (p<5% level), or the MMDT (global PTD ≥3.0).

The natural history of glaucoma means that in some people with early disease, structural changes precede functional loss, whilst in others functional abnormalities may be observed before detectable changes in structural parameters.[41] In the current study, thirty-two subjects fell into either category and were classified as 'glaucoma suspects'. Differentiating between suspects and normals presents a significant clinical challenge, as there is a substantial overlap of clinical characteristics between the groups. All four index tests showed poorer discrimination between normal subjects and POAG/glaucoma suspect groups combined than between those with confirmed glaucoma and the rest of the sample. The detection of glaucoma suspects requires a case

497 definition based on failure on either a structural or functional test. Whilst this
498 strategy is likely to improve sensitivity it is generally at the expense of
499 specificity. An alternative case-finding strategy is to use a Bayesian reasoning
500 approach. In clinical practice, a clinician will intuitively integrate the results of
501 diagnostic tests together with an estimate of the patient's pre-test probability of
502 disease based on age, IOP and family history of glaucoma to estimate an
503 individual's post-test probability. The probability of disease can be formally
504 estimated by calculations using the likelihood ratios of the diagnostic tests. The
505 results of independent tests can be combined in series to revise post-test
506 probability estimates.[42] However, the lack of true independence between
507 structural and functional criteria may lead to an overestimation of the combined
508 post-test probability. Nevertheless, this Bayesian approach could be used to
509 develop diagnostic algorithms and has great potential for glaucoma case-
510 finding or population screening pathways.[43]
511
512 The present study had a number of strengths: the design, analysis and
513 reporting complied with the principles of the STARD statement[14] and to reduce
514 spectrum bias the target population included consecutive subjects who met the
515 inclusion criteria. Although it is possible that higher numbers of those with
516 previous or family ocular history were more likely to volunteer and agree to
517 participate in the study, the prevalence of OAG in our population (5%) was
518 comparable with that expected for the age demographic. Furthermore, a wide
519 spectrum of disease severity was identified. We therefore feel the population is
520 likely to be broadly representative of those presenting for glaucoma case-
521 finding in the community. The reference standard for OAG corresponded to

that used in a typical hospital glaucoma unit and was based on the results of a standard ophthalmic examination by a validated clinician. At the present time, this examination represents the clinical reference standard for OAG, but as evidence accumulates it is anticipated that OCT may become part of this standard in the future. All index tests and the reference standard examination were undertaken on the same day, and the clinicians performing the reference and index tests were masked to the outcome of either. The study also has some limitations. The sample size of 505 subjects provided only 26 glaucoma subjects. This resulted in wide confidence intervals around our diagnostic sensitivity estimates, which may have masked real differences between index tests. Furthermore, almost 90% of our study population was of White European origin suggesting our findings may not be generalizable to other ethnic groups where glaucoma is more prevalent (e.g. subjects of Black origin). Data collection for this study was undertaken in dedicated research rooms based in a community eye clinic. In a real-world clinic setting, equipment may not be calibrated routinely and it is anticipated that diagnostic performance may be less good. Nevertheless, this study provides useful data to inform the development of further larger multi-center glaucoma screening studies.

Acknowledgements:

The authors wish to thank the UK College of Optometrists who provided a PhD studentship to Priya Dabasia, Optovue Inc. for the loan of the iVue OCT, and Tunde Peto (NIHR BMRC at Moorfields Eye Hospital NHS Foundation

Published in Ophthalmology
http://www.ncbi.nlm.nih.gov/pubmed/26411836

546 Trust and UCL Institute of Ophthalmology, London, UK) for providing the
547 medical retina images and facilitating the core-competency-based
548 assessments for the validation of the reference standard examiner.

549 **Legends for Figures 1 and 2**

550

551 Figure 1: Study flow diagram. FDT = frequency doubling technology perimeter;
552 MMDT = Moorfields motion displacement test; SD-OCT = spectral domain
553 optical coherence tomographer; ORA = ocular response analyzer; POAG =
554 primary open angle glaucoma; OHT = ocular hypertension.

555

556 Figure 2: Index test diagnostic effectiveness comparisons using ROC curves
557 with sensitivity at set specificity estimates and associated 95% confidence
558 intervals for detection of glaucoma suspect/POAG (primary open angle
559 glaucoma) combined (a) and POAG (b). FDT = Frequency Doubling
560 Technology Perimeter; MMDT = Moorfields motion displacement threshold
561 test; RNFL = retinal nerve fibre layer thickness.

562

REFERENCES

1. Bourne RR, Jonas JB, Flaxman SR, et al. Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe: 1990-2010. Br J Ophthalmol 2014;98:629-38.
2. Tielsch JM, Katz J, Singh K, et al. A population-based evaluation of glaucoma screening: the Baltimore Eye Survey. Am J Epidemiol 1991;134:1102-10.
3. Mitchell P, Smith W, Attebo K, et al. Prevalence of open-angle glaucoma in Australia. The Blue Mountains Eye Study. Ophthalmology 1996;103:1661-9.
4. Quigley HA & Vitale S. Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci 1997;38:83-91.
5. Wensor MD, McCarty CA, Stanislavsky YL, et al. The prevalence of glaucoma in the Melbourne Visual Impairment Project. Ophthalmology 1998;105:733-9.
6. Klein BE, Klein R, Sponsel WE, et al. Prevalence of glaucoma. The Beaver Dam Eye Study. Ophthalmology 1992;99:1499-504.
7. Dielemans I, Vingerling JR, Wolfs RC, et al. The prevalence of primary open-angle glaucoma in a population-based study in The Netherlands. The Rotterdam Study. Ophthalmology 1994;101:1851-5.
8. Weih LM, Nanjan M, McCarty CA, et al. Prevalence and predictors of open-angle glaucoma: results from the visual impairment project. Ophthalmology 2001;108:1966-72.
9. Wilson JMG & Jungner G. Principles and practice for screening for disease. Public Health Pap 1968;34.
10. Ervin AM, Boland MV, Myrowitz EH, et al. AHRQ Comparative Effectiveness Reviews. Screening for Glaucoma: Comparative Effectiveness. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012.
11. Burr JM, Mowatt G, Hernandez R, et al. The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation. Health Technol Assess 2007;11:iii-iv, ix-x, 1-190.
12. Mowatt G, Burr JM, Cook JA, et al. Screening tests for detecting open-angle glaucoma: systematic review and meta-analysis. Invest Ophthalmol Vis Sci 2008;49:5373-85.
13. Whiting P, Rutjes AW, Reitsma JB, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003;3:25.
14. Bossuyt PM, Reitsma JB, Bruns DE, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med 2003;138:W1-12.
15. Johnson CA. FDT perimetry for the detection of glaucomatous visual field loss. J Glaucoma Today 2008:26-8.
16. Patel SC, Friedman DS, Varadkar P, et al. Algorithm for interpreting the results of frequency doubling perimetry. Am J Ophthalmol 2000;129:323-7.
17. Aref AA & Budenz DL. Spectral domain optical coherence tomography in the diagnosis and management of glaucoma. Ophthalmic Surg Lasers Imaging 2010;41 Suppl:S15-27.
18. Sinai M. Direct Ganglion Cell Assessment with the RTVue: The Ganglion Cell Complex Analysis. Available from

612 http://adaptltda.com.br/conteudo/opto/rtvue_files/1281618322_directganglionc
613 ellassessmentwiththertvue_revb_final.pdf (accessed 19 December 2014).
614 2008.
615 19. Rao HL, Babu JG, Addepalli UK, et al. Retinal nerve fiber layer and
616 macular inner retina measurements by spectral domain optical coherence
617 tomograph in Indian eyes with early glaucoma. Eye (London, England)
618 2012;26:133-9.
619 20. Tan O, Chopra V, Lu AT, et al. Detection of macular ganglion cell loss in
620 glaucoma by Fourier-domain optical coherence tomography. Ophthalmology
621 2009;116:2305-14.
622 21. Terai N, Raiskup F, Haustein M, et al. Identification of biomechanical
623 properties of the cornea: the ocular response analyzer. Curr Eye Res
624 2012;37:553-62.
625 22. Vantomme M, Pourjavan S & Detry-Morel M. The range of the
626 waveform score of the ocular response analyzer (ora) in healthy subjects. Bull
627 Soc Belge Ophtalmol 2013:91-7.
628 23. Lam AK, Chen D & Tse J. The usefulness of waveform score from the
629 ocular response analyzer. Optom Vis Sci 2010;87:195-9.
630 24. Van Herick W, Shaffer RN & Schwartz A. Estimation of width of angle of
631 anterior chamber. Incidence and significance of the narrow angle. Am J
632 Ophthalmol 1969;68:626-9.
633 25. Anderson DR & Patella VM. Automated static perimetry (2nd ed.).
634 Mosby, St Louis, MO; 1999:147-159.
635 26. Reidy A, Minassian DC, Vafidis G, et al. Prevalence of serious eye
636 disease and visual impairment in a north London population: population based,
637 cross sectional study. BMJ 1998;316:1643-6.
638 27. Hillis SL & Metz CE. An analytic expression for the binormal partial area
639 under the ROC curve. Acad Radiol 2012;19:1491-8.
640 28. Pepe M, Longton G & Janes H. Estimation and Comparison of Receiver
641 Operating Characteristic Curves. The Stata journal 2009;9:1.
642 29. Hodapp E, Parrish IRK & Anderson DR. Clinical decisions in glaucoma.
643 St. Louis, The C.V, Mosby Co.; 1993:52-61.
644 30. Vaahtoranta-Lehtonen H, Tuulonen A, Aronen P, et al. Cost
645 effectiveness and cost utility of an organized screening programme for
646 glaucoma. Acta Ophthalmol Scand 2007;85:508-18.
647 31. Trikha S, Macgregor C, Jeffery M, et al. The Portsmouth-based
648 glaucoma refinement scheme: a role for virtual clinics in the future? Eye
649 (London, England) 2012;26:1288-94.
650 32. Rathod D, Win T, Pickering S, et al. Incorporation of a virtual
651 assessment into a care pathway for initial glaucoma management: Feasibility
652 study. Clinical and Experimental Ophthalmology 2008;36:543-6.
653 33. Robin TA, Muller A, Rait J, et al. Performance of community-based
654 glaucoma screening using Frequency Doubling Technology and Heidelberg
655 Retinal Tomography. Ophthalmic Epidemiol 2005;12:167-78.
656 34. Detry-Morel M, Zeyen T, Kestelyn P, et al. Screening for glaucoma in a
657 general population with the non-mydriatic fundus camera and the frequency
658 doubling perimeter. Eur J Ophthalmol 2004;14:387-93.
659 35. Ong EL, Zheng Y, Aung T, et al. Performance of the Moorfields motion
660 displacement test for identifying eyes with glaucoma. Ophthalmology
661 2014;121:88-92.

662 36. Jonas JB, Fernandez MC & Sturmer J. Pattern of glaucomatous
663 neuroretinal rim loss. Ophthalmology 1993;100:63-8.
664 37. Hood DC, Raza AS, de Moraes CG, et al. Glaucomatous damage of the
665 macula. Prog Retin Eye Res 2013;32:1-21.
666 38. AGIS. The Advanced Glaucoma Intervention Study (AGIS): 7. The
667 relationship between control of intraocular pressure and visual field
668 deterioration.The AGIS Investigators. Am J Ophthalmol 2000;130:429-40.
669 39. Heijl A, Leske MC, Hyman L, et al. Reduction of intraocular pressure
670 and glaucoma progression: Results from the Early Manifest Glaucoma Trial.
671 Arch Ophthalmol 2002;120:1268-79.
672 40. Saunders LJ, Russell RA, Kirwan JF, et al. Examining visual field loss in
673 patients in glaucoma clinics during their predicted remaining lifetime. Invest
674 Ophthalmol Vis Sci 2014;55:102-9.
675 41. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension
676 Treatment Study: a randomized trial determines that topical ocular hypotensive
677 medication delays or prevents the onset of primary open-angle glaucoma. Arch
678 Ophthalmol 2002;120:701-13; discussion 829-30.
679 42. Deeks JJ & Altman DG. Diagnostic tests 4: likelihood ratios. BMJ
680 2004;329:168-9.
681 43. Garway-Heath DF & Friedman DS. How should results from clinical
682 tests be integrated into the diagnostic process? Ophthalmology
683 2006;113:1479-80.
684

685


Eligible elderly population
N=505
Excluded
N=0
Technology-based index tests
(FDT, MMDT, SD-OCT, ORA)
N=505
Reference standard ophthalmic examination
N=505
Non-POAG/
Non-OHT
N=430 (85.1%)
Glaucoma
suspect
N=32 (6.4%)
Definite
POAG
N=26 (5.1%)
OHT
N=17 (3.4%)

686
687

688


1.0
0.8
0.6
0.4
0.2
0.0
Sensitivity
0.0
0.2
0.4
0.6
0.8
1.0
1-Specificity
FDT Patel et al. score
MMDT Global PTD
Inferior quadrant RNFL thickness


1.0
0.8
0.6
0.4
0.2
0.0
Sensitivity
0.0
0.2
0.4
0.6
0.8
1.0
1-Specificity
FDT Patel et al. score
MMDT Global PTD
Inferior quadrant RNFL thickness

689